Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo
Open Access
- 27 March 2015
- journal article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 12 (2), 1699-1708
- https://doi.org/10.3892/mmr.2015.3566
Abstract
Previous studies by our group showed that Qianliening capsules (QC), a clinically proven effective traditional Chinese formulation that has long been used in the treatment of benign prostatic hyperplasia (BPH), is capable of inhibiting BPH in vivo and in vitro via the promotion of apoptosis, suppression of the EGFR/STAT3 signaling pathway and regulating the expression of sex hormones as well as their receptors. However, the mechanism of its anti-BPH activity has remained to be fully elucidated. The present study aimed to investigate the mechanism underlying the anti-proliferative effect of QC in vivo and in vitro. Castrated male Sprage-Dawley (SD) rats where subcutaneously injected with testosterone propionate and the WPMY-1 cell line was stimulated with basic fibroblast growth factor in order to generate BPH in vivo and in vitro separately, both of which were then subjected to QC treatment. Finasteride was used as a positive control drug for the in vivo study. In the present study, it was found that treatment with QC or finasteride significantly reduced the prostatic index (PI=prostate wet weight/body weight × 100) in a rat model of BPH (P<0.05). In addition, reverse transcription quantitative polymerase chain reaction (RT-PCR) and western blot analyses showed that QC or finasteride treatment significantly inhibited model construction-induced upregulation of expression of proliferating cell nuclear antigen, cyclin D1 and cyclin-dependent kinase 4 in prostatic tissues of rats with BPH (P<0.05). The in vitro study further proved that QC exhibited anti-proliferative properties via G1/S cell cycle arrest in the WPMY-1 cell line, as evidenced by colony formation, flow cytometric cell cycle, immunoblot and RT-PCR analyses. In conclusion, the present study demonstrated that inhibition of cell proliferation via G1/S cell cycle arrest may be one of the underlying mechanisms of the effect of QC on BPH.Keywords
This publication has 34 references indexed in Scilit:
- Action Mechanism ofGinkgo bilobaLeaf Extract Intervened by Exercise Therapy in Treatment of Benign Prostate HyperplasiaEvidence-Based Complementary and Alternative Medicine, 2013
- Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathwayExperimental and Therapeutic Medicine, 2013
- Inhibitory effect of Yukmijihwang-tang, a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in ratsBMC Complementary and Alternative Medicine, 2012
- Crystal structure of human CDK4 in complex with a D-type cyclinProceedings of the National Academy of Sciences of the United States of America, 2009
- Pathology of benign prostatic hyperplasiaInternational Journal of Impotence Research, 2008
- Selectivity and potency of cyclin-dependent kinase inhibitorsThe AAPS Journal, 2006
- Interleukin-8 Is a Paracrine Inducer of Fibroblast Growth Factor 2, a Stromal and Epithelial Growth Factor in Benign Prostatic HyperplasiaThe American Journal of Pathology, 2001
- Cell Kinetic in Epithelium and Stroma of Benign Prostatic HyperplasiaJournal of Urology, 1997
- Principles of CDK regulationNature, 1995
- Increased expression of genes for basic fibroblast growth factor and transforming growth factor type β2 in human benign prostatic hyperplasiaThe Prostate, 1990